-
Pharmaceutical companies have intensively ushered in high-level personnel changes, and the positions of general managers/deputy general managers have changed frequently
Time of Update: 2022-08-15
. The pharmaceutical company has changed 9 times in the past year, and Renhe Pharmaceutical issued an announcement at noon on July 26, saying that the company's board of directors received the company's director and general manager, Mr. Zhang Wei, and deputy general manager, Mr. Wang Zhen, on July 26, 2022.
-
Innovative drug license out is getting better, another company sells overseas rights and interests of research products
Time of Update: 2022-08-15
[Pharmaceutical Network Industry News] On July 28, CSPC announced that its subsidiary CSPC Jushi Bio has reached an agreement with Elevation Oncology, an American biopharmaceutical company, which obtained CSPC Jushi Bio-antibody-conjugated drug (ADC) SYSA1801 in Exclusive license agreement for development and commercialization outside of Greater China (including Mainland China, Hong Kong, Macau and Taiwan) .
-
Aiming at the broad domestic pharmaceutical equipment market, the construction of new projects for pharmaceutical machine companies is in full swing
Time of Update: 2022-08-15
It is understood that on February 7, the construction of the Chutian Technology 10-billion-capacity intelligent manufacturing base project started in Ningxiang City, and before that, Chutian Technology has completed the fourth phase of construction in 2021 .
-
2022H1GSK performance: the structural adjustment has achieved initial results, the performance of star products has reached a new high, and the full-year forecast has been raised
Time of Update: 2022-08-15
Among them, the anti-PD-1 antibody Jemperli (dostarlimab, dotalimab) developed by the company was granted accelerated approval by the FDA in April 2021 for the treatment of patients with disease progression after receiving platinum-containing chemotherapy and carrying mismatch repair deficiency (dMMR) DNA repair abnormalities.
-
Sihuan Pharmaceutical spins off "cash cow" generic drugs, why is the pain of generic innovation and upgrading?
Time of Update: 2022-08-15
Recently, Sihuan Pharmaceutical announced that it plans to sell some or all of the generic drugs and other non-core traditional medicine businesses and assets that have not met performance expectations or are not in line with the company's long-term strategic goals due to the impact of changes in the pharmaceutical industry and policies .
-
The New Deal is here, and the biopharmaceutical equipment industry is welcome!
Time of Update: 2022-08-15
"Enhancing the supply chain security level of high-end biopharmaceutical products and equipment" has been written into the "14th Five-Year Plan for Bioeconomic Development".
"Enhancing the supply chain security level of high-end biopharmaceutical products and equipment" has been written into the "14th Five-Year Plan for Bioeconomic Development".
-
What are the key cases of the online seminar on heavy metal contaminated soil treatment?
Time of Update: 2022-08-15
, Ltd. Hao Jianqing, director of the Soil Remediation Office of the Ecological Environment Division, carried out the heavy metal pollution site treatment technology and engineering case sharing .
-
The national centralized procurement has saved a total of 300 billion!
Time of Update: 2022-08-15
On July 22, the National Health and Health Commission held a press conference. The responsible comrades of the National Health and Health Commission, the National Development and Reform Commission, t
-
new highs!
Time of Update: 2022-08-15
According to the announcement, WuXi AppTec attributed its performance growth in the first half of the year to the company's continued strengthening of its unique integrated CRDMO (Contract Research, Development and Production) and CTDMO (Contract Testing, R&D and Production) business models, while actively cooperating with the implementation of Shanghai Regional new crown pneumonia epidemic prevention and control measures, give full play to the advantages of global layout, multi-location operation and the entire industry chain coverage .
-
On August 5th, listed pharmaceutical companies announced review, increase and decrease of holdings, resignation, etc.
Time of Update: 2022-08-15
[Pharmaceutical Network Industry News] On August 5, a large number of listed pharmaceutical companies issued announcements, involving matters such as over-evaluation, increase or decrease in holdings, and resignation.
-
There are 12 self-paid medicines in the collection of 18 varieties!
Time of Update: 2022-08-15
. It is worth mentioning that both diosmin and compound α-ketoacid are clearly required for oral normal-release dosage forms in the bulk purchase of eight provinces and two districts, but the current problem is that these two varieties of tablets The medicine belongs to the national medical insurance, while the capsule belongs to the non-medical insurance .
-
Chain pharmacies are about to enter the "10,000-store era", and the "big eats" and "big eats" mergers and acquisitions are accelerating
Time of Update: 2022-08-15
have basically completed the online channel layout At present, leading chain pharmacies including Yixintang, Common People, Yifeng Pharmacy, Dashenlin, Jianzhijia, Shuyu Civilian, etc.
-
Policy review: how provincial medical insurance policies inject new momentum into the development of traditional Chinese medicine
Time of Update: 2022-08-15
Gansu Province proposed to promote the development of "smart Chinese pharmacies", improve the level of pharmaceutical services such as TCM decoction pieces and formulations, and realize the integration of TCM decoction pieces procurement and storage, prescription circulation, medical insurance settlement, preparation and decoction, centralized distribution, and quality management in medical institutions.
-
It is not easy for domestic new drugs to go overseas, this pharmaceutical company initiated another breakthrough!
Time of Update: 2022-08-15
It is not easy for domestic new drugs to go overseas In March this year, Innovent announced that the “going overseas” had failed, and the marketing application of its core product sintilimab was not approved by the US FDA .
-
A large number of enterprises take the initiative to cancel the "Medical Device Registration Certificate"!
Time of Update: 2022-08-15
[Pharmaceutical Network Industry News] On August 2, the State Food and Drug Administration announced that in accordance with the relevant provisions of the "Regulations on the Supervision and Administration of Medical Devices", according to the application of enterprises, the registration certificates of medical devices for 6 products are now cancelled .
-
Roche, Johnson & Johnson and many other multinational pharmaceutical companies announced their 2022 semi-annual financial reports. How about the "transcript"?
Time of Update: 2022-08-15
3%; consumption According to the sales data in the first half of the year, the revenue of the pharmaceutical business was US$26.
According to the data, Novartis’ net sales revenue in the first half of the year reached US$25.
-
Can cure the new crown?
Time of Update: 2022-08-15
Concept stocks soared, and many companies were busy clarifying What Tong Yigang did not expect was that this report also caused a skyrocketing rise in related traditional Chinese medicine stocks .
-
In the face of the retired tide lithium battery recycling online seminar, you can step on the "points"!
Time of Update: 2022-08-15
[Pharmaceutical Network Conference Forum] Under the background of "dual carbon", the development of clean energy comes first and the energy storage industry develops later, both of which are insepara
-
Darui Bio Announces Exclusive Licensing Deal with Sanofi for Small Nucleic Acid Pipeline and Technology Platform
Time of Update: 2022-08-15
Exclusive worldwide license to the modification and delivery platform, and preclinical drug candidates for four undisclosed targets Darui Biomedical Technology (Shanghai) Co.
Exclusive worldwide license to the modification and delivery platform, and preclinical drug candidates for four undisclosed targets Darui Biomedical Technology (Shanghai) Co.
-
32 pharmaceutical companies raised more than 30 billion yuan!
Time of Update: 2022-08-15
5 billion yuan, which will be invested in projects such as global headquarters and innovation and industrialization bases, peripheral vascular intervention and tumor intervention medical device research and development, and replenishment of working capital For example, Xinmai Medical announced on July 25 that it has launched a fixed increase plan of 2.
